Abeona Therapeutics Inc. (ABEO)
Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright
Abeona Therapeutics NASDAQ: ABEO highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the H.C. Wainwright 28th Annual conference.
Abeona Therapeutics Inc. (ABEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Abeona Therapeutics Inc. (ABEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Abeona Therapeutics: Earnings Sell-Off Could Be A Buy Opportunity
Abeona Therapeutics reported Q2 revenues of $11.4m, treating five Zevaskyn patients, but missed analyst expectations, leading to a 14% stock drop. Operational setbacks in Zevaskyn's rollout, including cancellations and manufacturing issues, highlight a steep learning curve, but management expects improvement as experience grows. Partnered programs with Ultragenyx and Taysha offer potential near-term catalysts, with milestone and royalty payments possible if approvals and sales targets are met.
Abeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcript
Abeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcript
Abeona Therapeutics Q2 Earnings Call Highlights
Abeona Therapeutics NASDAQ: ABEO reported second-quarter revenue growth from its ZEVASKYN cell therapy launch while outlining operational challenges involving patient scheduling and manufacturing that affected revenue recognition.
Abeona Therapeutics Inc. (ABEO) Q1 2026 Earnings Call Transcript
Abeona Therapeutics Inc. (ABEO) Q1 2026 Earnings Call Transcript
Abeona Therapeutics Q1 Earnings Call Highlights
Abeona Therapeutics NASDAQ: ABEO reported early commercial momentum for ZEVASKYN in the first quarter of 2026, with executives highlighting new patient treatments, expanded treatment-center activation and a newly licensed prostate cancer cell therapy program during the company's earnings call.
Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB
Abeona Therapeutics maintains a "Buy" rating, driven by ZEVASKYN's commercial launch for RDEB and strong early demand signals. ZEVASKYN is the first autologous cell sheet-based gene therapy for RDEB, with FDA approval and broad payer access, targeting a >$4B cumulative revenue opportunity. Profitability is achievable by treating just three RDEB patients per month; demand doubled from 50 to 100 eligible patients, with seven QTCs expected by year-end 2026.
Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript
Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript
Abeona Therapeutics Q3 2025: Strong Financials And Zevaskyn Launch Ahead
Abeona Therapeutics delivered strong 3Q25 results, with a narrowed net loss and $207.5 million in cash supporting a two-year runway. Zevaskyn's commercial launch is delayed to 4Q25 due to FDA assay requirements, but demand and payer coverage remain robust, aided by a new CMS J-code. ABEO's financials improved significantly, with reduced R&D expenses and a strengthened balance sheet, positioning the company well for commercialization.
Abeona Therapeutics Inc. (ABEO) Q3 2025 Earnings Call Transcript
Abeona Therapeutics Inc. ( ABEO ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Gregory Gin - Vice President of Investor Relations & Corporate Communications Vishwas Seshadri - President, CEO & Director Brian Kevany - Senior VP, CTO & CSO Madhav Vasanthavada - Senior VP, Chief Commercial Officer & Head of Business Development Joseph Vazzano - Chief Financial Officer Conference Call Participants Mohamad Amin Makarem - Jefferies LLC, Research Division Rick Miller - Cantor Fitzgerald & Co., Research Division Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Jeffrey Jones - Oppenheimer & Co. Inc., Research Division David Bautz - Zacks Small-Cap Research Presentation Operator Good morning, everyone, and welcome to the Abeona Therapeutics Third Quarter 2025 Conference Call.
Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript
Abeona Therapeutics Inc. (NASDAQ:ABEO ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Brian Kevany - Senior VP, CTO & CSO Gregory Gin - Vice President of Investor Relations & Corporate Communications Joseph Walter Vazzano - Chief Financial Officer Madhav Vasanthavada - Senior VP, Chief Commercial Officer & Head of Business Development Vishwas Seshadri - President, CEO & Director Conference Call Participants James Francis Molloy - Alliance Global Partners, Research Division Jeffrey Michael Jones - Oppenheimer & Co. Inc., Research Division Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Operator Good Day everyone, and welcome to the Abeona Therapeutics Second Quarter 2025 Conference Call.
